CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2015;2(4):269-396 | 37784 |
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2016;4:262-379 | 17822 |
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(2):128-135 | 6967 |
THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION | J Prev Alz Dis 2015;2(4):254-266 | 6715 |
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK | J Prev Alz Dis 2016;3(2):114-120 | 5709 |
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S55-S119 | 5039 |
VITAMIN D AND DEMENTIA | J Prev Alz Dis 2016;3(1):43-52 | 4634 |
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) | J Prev Alz Dis 2015;2(4):227-241 | 3965 |
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL | J Prev Alz Dis 2017;4(3):149-156 | 3611 |
A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2016;3(3):133-137 | 3470 |
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” | J Prev Alz Dis 2016;3(4):219-228 | 3133 |
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES | J Prev Alz Dis 2017;4(4):236-241 | 2896 |
REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR | J Prev Alz Dis 2016;3(4):202-218 | 2879 |
BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):30-42 | 2673 |
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):109-115 | 2616 |
CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCE | J Prev Alz Dis 2015;2(2):115-120 | 2371 |
ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCH | J Prev Alz Dis 2017;4(2):125-131 | 2361 |
NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):273-278 | 2294 |
COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER | J Prev Alz Dis 2016;3(3):164-172 | 2234 |
THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):78-84 | 2208 |
BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTION | J Prev Alz Dis 2015;2(3):189-198 | 2177 |
EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIA | J Prev Alz Dis 2017;4(3):201-206 | 2025 |
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):242-246 | 1999 |
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM | J Prev Alz Dis 2015;2(3):165-171 | 1995 |
FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACH | J Prev Alz Dis 2017;4(3):157-164 | 1933 |
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2017;4(1):12-15 | 1905 |
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA | J Prev Alz Dis 2014;1(1):13-22 | 1844 |
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(3):138-144 | 1836 |
SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2021;1(8):7-18 | 1569 |
B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL | J Prev Alz Dis 2017;4(3):174-182 | 1539 |
ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):157-163 | 1535 |
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS | J Prev Alz Dis 2016;3(4):229-235 | 1502 |
THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS | J Prev Alz Dis 2017;4(3):183-193 | 1488 |
DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY | J Prev Alz Dis 2017;4(2):72-80 | 1472 |
ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020 | J Prev Alz Dis 2020;7(2):66-67 | 1431 |
THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2016;3(3):173-176 | 1425 |
RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD) | J Prev Alz Dis 2016;3(4):236-242 | 1424 |
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMS | J Prev Alz Dis 2019;6(1):27-33 | 1397 |
HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2020;7(1):47-55 | 1358 |
FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL | J Prev Alz Dis 2018;5(3):168-170 | 1291 |
VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODEL | J Prev Alz Dis 2017;4(4):226-235 | 1264 |
IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2018;5(2):98-102 | 1226 |
INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORT | J Prev Alz Dis 2020;7(2):70-74 | 1211 |
NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):155-156 | 1169 |
PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION | J Prev Alz Dis 2021;2(8):151-160 | 1137 |
WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE | J Prev Alz Dis 2018;5(3):171-170 | 1130 |
THE FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):146-151 | 1101 |
PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2019;6(3):169-173 | 1100 |
REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2016;3(2):68-74 | 1068 |
NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020 | J Prev Alz Dis 2021;2(8):118-122 | 1063 |
PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSIS | J Prev Alz Dis 2018;5(4):253-258 | 1058 |
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERS | J Prev Alz Dis 2020;7(1):29-36 | 1010 |
NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2020;3(7):152-157 | 1009 |
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S2-S54 | 996 |
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE | J Prev Alz Dis 2020;3(7):165-170 | 990 |
AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTH | J Prev Alz Dis 2018;5(3):207-212 | 989 |
APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY | J Prev Alz Dis 2019;6(4):248-255 | 971 |
THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0 | J Prev Alz Dis 2020;7(1):8-13 | 955 |
IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS | J Prev Alz Dis 2019;6(2):78-84 | 937 |
UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):90-99 | 889 |
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES | J Prev Alz Dis 2020;3(7):158-164 | 879 |
THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAIN | J Prev Alz Dis 2020;4(7):265-273 | 861 |
A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONS | J Prev Alz Dis 2020;4(7):291-293 | 861 |
A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIAS | J Prev Alz Dis 2019;6(4):214-216 | 855 |
CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE? | J Prev Alz Dis 2019;6(4):217-220 | 853 |
TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | J Prev Alz Dis 2020;3(7):184-194 | 812 |
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS | J Prev Alz Dis 2017;4(2):116-124 | 798 |
CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION | J Prev Alz Dis 2020;7(2):128-134 | 786 |
REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE | J Prev Alz Dis 2020;7(1):56-64 | 778 |
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING | J Prev Alz Dis 2020;3(7):171-178 | 762 |
IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISIS | J Prev Alz Dis 2020;3(7):197-198 | 753 |
ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):232-236 | 735 |
ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):85-87 | 717 |
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS | J Prev Alz Dis 2015;2(2):82-84 | 707 |
CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL | J Prev Alz Dis 2018;5(3):202-206 | 704 |
SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY? | J Prev Alz Dis 2020;3(7):144-145 | 694 |
POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELES | J Prev Alz Dis 2019;6(1):16-19 | 688 |
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):213-218 | 678 |
POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2015;2(2):88-90 | 672 |
THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMS | J Prev Alz Dis 2020;4(7):288-290 | 672 |
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):398-410 | 664 |
DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNS | J Prev Alz Dis 2019;6(1):50-55 | 660 |
THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTION | J Prev Alz Dis 2021;3(8):313-321 | 660 |
TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;2(9):197-210 | 659 |
IMPACT OF ADUHELM APPROVAL ON CARE AND POLICY | J Prev Alz Dis 2021;4(8):396-397 | 656 |
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIAL | J Prev Alz Dis 2021;1(8):59-67 | 653 |
THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIES | J Prev Alz Dis 2020;4(7):242-250 | 643 |
TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARS | J Prev Alz Dis 2019;6(1):42-49 | 642 |
HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH? | J Prev Alz Dis 2021;4(8):391-392 | 637 |
A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP | J Prev Alz Dis 2020;4(7):274-282 | 629 |
EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYS | J Prev Alz Dis 2022;4(9):758-768 | 627 |
APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINE | J Prev Alz Dis 2021;2(8):123-126 | 622 |
DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDY | J Prev Alz Dis 2021;2(8):127-134 | 598 |
THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMAB | J Prev Alz Dis 2021;1(8):3-6 | 593 |
TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMIC | J Prev Alz Dis 2020;4(7):301-304 | 590 |
DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021 | J Prev Alz Dis 2021;3(8):371-386 | 584 |
NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGY | J Prev Alz Dis 2020;3(7):138-139 | 570 |
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW | J Prev Alz Dis 2020;4(7):208-212 | 562 |
THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICE | J Prev Alz Dis 2021;4(8):411 | 547 |
NEW HOPE FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):238-239 | 532 |
PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALS | J Prev Alz Dis 2022;2(9):241-246 | 532 |
CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCH | J Prev Alz Dis 2021;4(8):393-395 | 524 |
THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARS | J Prev Alz Dis 2020;4(7):234-241 | 523 |
POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):78-83 | 513 |
LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):299-300 | 508 |
THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALS | J Prev Alz Dis 2020;7(1):7 | 500 |
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):412-413 | 484 |
INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):240-248 | 481 |
RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD) | J Prev Alz Dis 2020;4(7):219-225 | 460 |
AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM | J Prev Alz Dis 2021;2(8):218-223 | 460 |
THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):294-298 | 448 |
AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):300 | 446 |
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S73-S170 | 428 |
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA | J Prev Alz Dis 2021;3(8):257-262 | 419 |
ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTS | J Prev Alz Dis 2020;4(7):202-203 | 417 |
TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGY | J Prev Alz Dis 2020;4(7):226-233 | 414 |
ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATION | J Prev Alz Dis 2020;4(7):204-205 | 412 |
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S1-S72 | 397 |
LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDY | J Prev Alz Dis 2021;2(8):199-209 | 369 |
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH | J Prev Alz Dis 2020;4(7):206-207 | 333 |
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) | J Prev Alz Dis 2021;4(8):425-435 | 327 |
PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;3(8):306-312 | 316 |
VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’? | J Prev Alz Dis 2023;3(10):342-343 | 314 |
ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2021;4(8):462-464 | 313 |
THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;2(9):231-235 | 312 |
DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONS | J Prev Alz Dis 2022;1(9):1-2 | 306 |
CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS? | J Prev Alz Dis 2021;3(8):387-388 | 297 |
MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVE | J Prev Alz Dis 2022;1(9):3-11 | 293 |
THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAM | J Prev Alz Dis 2021;3(8):286-291 | 292 |
DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGING | J Prev Alz Dis 2021;4(8):414-424 | 290 |
MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEW | J Prev Alz Dis 2021;3(8):362-370 | 283 |
COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMER | J Prev Alz Dis 2021;1(8):68-77 | 280 |
BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2022;1(9):12-21 | 268 |
MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESS | J Prev Alz Dis 2022;1(9):30-39 | 267 |
USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;4(8):513-519 | 265 |
WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONS | J Prev Alz Dis 2022;3(9):550-555 | 256 |
DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD) | J Prev Alz Dis 2022;2(9):236-240 | 254 |
A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMME | J Prev Alz Dis 2021;4(8):448-456 | 250 |
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATE | J Prev Alz Dis 2022;2(9):221-230 | 247 |
THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):393-399 | 243 |
DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPY | J Prev Alz Dis 2022;2(9):211-220 | 233 |
SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISK | J Prev Alz Dis 2022;4(9):731-742 | 222 |
EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENT | J Prev Alz Dis 2022;3(9):385-386 | 219 |
ORAL HEALTH AS A RISK FACTOR FOR ALZHEIMER DISEASE | | 219 |
WHERE DO WE GO FROM HERE? | J Prev Alz Dis 2022;2(9):188-189 | 215 |
AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOID | J Prev Alz Dis 2022;4(9):617-624 | 215 |
COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEW | J Prev Alz Dis 2021;4(8):520-533 | 212 |
THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2022;1(9):96-103 | 211 |
DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA | J Prev Alz Dis 2022;3(9):499-506 | 206 |
SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGM | J Prev Alz Dis 2022;3(9):542-549 | 205 |
CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):507-522 | 205 |
BUNTANETAP, A NOVEL TRANSLATIONAL INHIBITOR OF MULTIPLE NEUROTOXIC PROTEINS, PROVES TO BE SAFE AND PROMISING IN BOTH ALZHEIMER’S AND PARKINSON’S PATIENTS | J Prev Alz Dis 2023;1(10):25-33 | 198 |
EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTION | J Prev Alz Dis 2022;1(9):49-53 | 196 |
ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGE | J Prev Alz Dis 2022;2(9):193-196 | 196 |
MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;3(9):458-468 | 193 |
TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):388-392 | 191 |
CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):255-263 | 190 |
THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING? | J Prev Alz Dis 2022;2(9):190-192 | 187 |
BASELINE FINDINGS OF PREVENTE4: A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL TRIAL TESTING HIGH DOSE DHA IN APOE4 CARRIERS BEFORE THE ONSET OF DEMENTIA | J Prev Alz Dis 2023;4(10):810-820 | 184 |
IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUM | J Prev Alz Dis 2022;4(9):769-779 | 182 |
EDITORIAL: APPROPRIATE USE RECOMMENDATIONS FOR LECANEMAB | J Prev Alz Dis 2023;3(10):356 | 182 |
LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;1(9):178-183 | 181 |
THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLAND | J Prev Alz Dis 2022;2(9):348-358 | 180 |
LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDY | J Prev Alz Dis 2022;1(9):126-135 | 179 |
A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):469-479 | 179 |
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT? | J Prev Alz Dis 2019;6(3):150 | 177 |
UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINE | J Prev Alz Dis 2022;2(9):262-268 | 176 |
ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDY | J Prev Alz Dis 2022;1(9):86-91 | 176 |
ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATE | J Prev Alz Dis 2022;4(9):780-790 | 176 |
LECANEMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2023;3(10):362-377 | 176 |
VIEWPOINT: WHAT IS REASONABLE AND NECESSARY FOR PEOPLE LIVING WITH AD AFTER THE FDA APPROVES A TREATMENT? | J Prev Alz Dis 2023;3(10):344-345 | 175 |
SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENT | J Prev Alz Dis 2022;4(9):692-700 | 172 |
COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGE | J Prev Alz Dis 2022;4(9):791-800 | 169 |
EDITORIAL: THE FUTURE IS NOW: ADVANCING BLOOD-BASED MARKERS | J Prev Alz Dis 2022;4(9):563-564 | 167 |
LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY? | J Prev Alz Dis 2022;4(9):813-815 | 164 |
VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALE | J Prev Alz Dis 2022;2(9):269-276 | 163 |
LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDY | J Prev Alz Dis 2022;1(9):151-157 | 158 |
EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT! | J Prev Alz Dis 2022;3(9):387 | 158 |
THE USE OF EPISODIC MEMORY TESTS FOR SCREENING IN CLINICAL TRIALS FOR EARLY ALZHEIMER’S DISEASE: A COMPARISON OF THE FREE AND CUED SELECTIVE REMINDING TEST (FCSRT) AND THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS) | J Prev Alz Dis 2023;1(10):41-49 | 157 |
INVESTIGATING PARTIALLY DISCORDANT RESULTS IN PHASE 3 STUDIES OF ADUCANUMAB | J Prev Alz Dis 2023;2(10):171-177 | 157 |
A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;2(9):255-261 | 156 |
EDITORIAL: WHAT ARE THE REMAINING CHALLENGES BEFORE BLOODBASED BIOMARKERS FOR ALZHEIMER’S DISEASE CAN BE USED IN CLINICAL PRACTICE? | J Prev Alz Dis 2022;4(9):567-568 | 155 |
ESTABLISHING CLINICALLY MEANINGFUL CHANGE ON OUTCOME ASSESSMENTS FREQUENTLY USED IN TRIALS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):9-18 | 151 |
EDITORIAL: BLOOD-BASED BIOMARKERS FOR ALZHEIMER’S DISEASE: ARE WE THERE YET? | J Prev Alz Dis 2022;4(9):565-566 | 150 |
BLOOD BIOMARKERS FROM RESEARCH USE TO CLINICAL PRACTICE: WHAT MUST BE DONE? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2022;4(9):569-579 | 150 |
ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION | J Prev Alz Dis 2022;3(9):491-498 | 149 |
ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIAL | J Prev Alz Dis 2022;4(9):625-634 | 148 |
ACU193, A MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS SOLUBLE ASS OLIGOMERS: DEVELOPMENT RATIONALE, PHASE 1 TRIAL DESIGN, AND CLINICAL DEVELOPMENT PLAN | J Prev Alz Dis 2023;1(10):19-24 | 148 |
THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSE | J Prev Alz Dis 2022;4(9):580-588 | 147 |
EDITORIAL: WHAT IS REASONABLE AND NECESSARY FOR ALZHEIMER PATIENTS FROM RANDOMIZED CLINICAL TRIALS TO CLINICAL PRACTICE? | J Prev Alz Dis 2023;3(10):331-332 | 142 |
GENDER-SPECIFIC DESIGN AND EFFECTIVENESS OF NONPHARMACOLOGICAL INTERVENTIONS AGAINST COGNITIVE DECLINE – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2023;1(10):69-82 | 141 |
EDITORIAL: CLINICAL IMPLEMENTATION OF LECANEMAB: CHALLENGES, QUESTIONS AND SOLUTIONS | J Prev Alz Dis 2023;3(10):353-355 | 141 |
EDITORIAL: CHANGE ON CLINICAL TRIAL OUTCOME ASSESSMENTS: THE SEARCH FOR MEANINGFULNESS | J Prev Alz Dis 2023;1(10):5-6 | 135 |
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S8-S50 | 133 |
ANTIHYPERTENSIVE AGENTS AND INCIDENT ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES | J Prev Alz Dis 2022;4(9):715-724 | 127 |
SYSTEMATIC AND COMPARATIVE ANALYSIS OF THE BURDEN OF ALZHEIMER´S DISEASE AND OTHER DEMENTIAS IN MEXICO. RESULTS AT THE NATIONAL AND SUBNATIONAL LEVELS, 1990- 2019 | J Prev Alz Dis 2023;1(10):120-129 | 127 |
DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECH | J Prev Alz Dis 2017;4(4):264-272 | 124 |
EDITORIAL: EXPANDING THE ATN FRAMEWORK TO FURTHER PERSONALIZE THERAPIES | J Prev Alz Dis 2023;3(10):380 | 122 |
ASSOCIATIONS BETWEEN PARTICIPANT CHARACTERISTICS AND PARTICIPANT FEEDBACK ABOUT AN UNSUPERVISED ONLINE COGNITIVE ASSESSMENT IN A RESEARCH REGISTRY | J Prev Alz Dis 2023;3(10):607-614 | 120 |
ARE POPULATION-LEVEL APPROACHES TO DEMENTIA RISK REDUCTION UNDER-RESEARCHED? A RAPID REVIEW OF THE DEMENTIA PREVENTION LITERATURE | | 118 |
THE GERAS SOLUTIONS COGNITIVE TEST FOR ASSESSING COGNITIVE IMPAIRMENT: NORMATIVE DATA FROM A POPULATION-BASED COHORT | J Prev Alz Dis 2023;2(10):207-211 | 117 |
EDITORIAL: LECANEMAB: APPROPRIATE USE RECOMMENDATIONS – A COMMENTARY FROM A EUROPEAN PERSPECTIVE | J Prev Alz Dis 2023;3(10):357-358 | 117 |
LETTER TO THE EDITOR: AMBAR: A THERAPEUTICAL APPROACH FOR ALZHEIMER’S DISEASE PATIENTS REGARDLESS OF AMYLOID STATUS | J Prev Alz Dis 2023;1(10):148-149 | 115 |
DEVELOPMENT OF A MOBILE-FIRST REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):857-864 | 114 |
VIEWPOINT «COMPOUNDED INTEREST» IN ALZHEIMER’S DISEASE: DO NEW AMYLOID-TARGETING TREATMENTS JUSTIFY THEIR USE | J Prev Alz Dis 2023;3(10):333-335 | 114 |
VIEWPOINT: AMYLOID-TARGETING NEW THERAPIES FOR ALZHEIMER’S DISEASE: A HEALTH ECONOMICS PERSPECTIVE | J Prev Alz Dis 2023;3(10):349-352 | 114 |
EDITORIAL: ACCELERATING INNOVATIONS FOR ENHANCED BRAIN HEALTH. CAN ARTIFICIAL INTELLIGENCE ADVANCE NEW PATHWAYS FOR DRUG DISCOVERY FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISORDERS? | J Prev Alz Dis 2023;1(10):1-4 | 113 |
BURDEN OF ILLNESS IN PEOPLE WITH ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF EPIDEMIOLOGY, COMORBIDITIES AND MORTALITY | | 113 |
REDUCING THE EFFECTS OF AGEING ON COGNITION WITH THERAPEUTIC INTERVENTION OF AN ORAL MULTI-NUTRIENT: THE REACTION PILOT TRIAL STUDY DESIGN | J Prev Alz Dis 2023;4(10):821-827 | 112 |
PROTOCOL OF A PHASE II RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF S-ADENOSYL METHIONINE IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):800-809 | 111 |
EDITORIAL: USEFULNESS OF ANCHOR BASED METHODS FOR DETERMINING CLINICALLY MEANINGFUL CHANGE IN MCI DUE TO AD | J Prev Alz Dis 2023;1(10):7-8 | 107 |
VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIES | J Prev Alz Dis 2023;3(10):336-338 | 107 |
THE ROLE OF THYROID DYSFUNCTION IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;2(10):276-286 | 104 |
DIAGNOSTIC BIOMARKERS OF AMYLOID AND TAU PATHOLOGY IN ALZHEIMER’S DISEASE: AN OVERVIEW OF TESTS FOR CLINICAL PRACTICE IN THE UNITED STATES AND EUROPE | J Prev Alz Dis 2023;3(10):426-442 | 104 |
CROSS-SECTIONAL AND LONGITUDINAL COMPARISON OF TAU IMAGING WITH 18F-MK6240 AND 18F-FLORTAUCIPIR IN POPULATIONS MATCHED FOR AGE, MMSE AND BRAIN BETA-AMYLOID BURDEN | J Prev Alz Dis 2023;2(10):251-258 | 103 |
CAN WE USE BLOOD BIOMARKERS AS ENTRY CRITERIA AND FOR MONITORING DRUG TREATMENT EFFECTS IN CLINICAL TRIALS? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2023;3(10):418-425 | 102 |
PREFERENCES ABOUT FUTURE ALZHEIMER’S DISEASE TREATMENTS ELICITED THROUGH AN ONLINE SURVEY USING THE THRESHOLD TECHNIQUE | J Prev Alz Dis 2023;4(10):756-764 | 102 |
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2017;4(4):282-428 | 100 |
PREDICTING PROGRESSION FROM NORMAL TO MCI AND FROM MCI TO AD USING CLINICAL VARIABLES IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER UNIFORM DATA SET VERSION 3: APPLICATION OF MACHINE LEARNING MODELS AND A PROBABILITY CALCULATOR | J Prev Alz Dis 2023;2(10):301-313 | 100 |
VIEWPOINT: CLINICIANS’ PERSPECTIVES ON HOW DISEASE MODIFYING DRUGS FOR ALZHEIMER’S DISEASE IMPACT SPECIALTY CARE | J Prev Alz Dis 2023;3(10):339-341 | 100 |
UTILITY OF ENVIRONMENTAL COMPLEXITY AS A PREDICTOR OF ALZHEIMER’S DISEASE DIAGNOSIS: A BIG-DATA MACHINE LEARNING APPROACH | J Prev Alz Dis 2023;2(10):223-235 | 99 |
UNDERSTANDING BARRIERS AND FACILITATORS TO SIGNING UP FOR A MOBILE-RESPONSIVE REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):865-874 | 98 |
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S51-S248 | 97 |
COMMENTARY: CLINICAL EFFICACY IN INDIVIDUAL PATIENTS TREATED WITH LECANEMAB | J Prev Alz Dis 2023;3(10):378-379 | 96 |
COMBINED EVIDENCE FOR A LONG-TERM, CLINICAL SLOWING EFFECT OF MULTINUTRIENT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: POST-HOC ANALYSIS OF 3-YEAR DATA FROM THE LIPIDIDIET TRIAL | J Prev Alz Dis 2023;3(10):464-470 | 95 |
PUSHING THROUGH THE BARRIERS: PEER ADVICE TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEMENTIA RISK FROM PARTICIPANTS IN A MASSIVE OPEN ONLINE ALZHEIMER’S FOCUSED COURSE | J Prev Alz Dis 2023;3(10):503-512 | 95 |
UNDERSTANDING ONLINE REGISTRY FACILITATORS AND BARRIERS EXPERIENCED BY BLACK BRAIN HEALTH REGISTRY PARTICIPANTS: THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY | J Prev Alz Dis 2023;3(10):551-561 | 95 |
OUTREACH, SCREENING, AND RANDOMIZATION OF APOE Ε4 CARRIERS INTO AN ALZHEIMER’S PREVENTION TRIAL: A GLOBAL PERSPECTIVE FROM THE API GENERATION PROGRAM | J Prev Alz Dis 2023;3(10):453-463 | 93 |
ASSOCIATION BETWEEN NEUROPSYCHOLOGICAL PERFORMANCE AND CSF PROFILE IN SUBJECTIVE COGNITIVE DECLINE: TOWARDS THE DIAGNOSIS OF PRECLINICAL AD | J Prev Alz Dis 2023;3(10):523-529 | 93 |
‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGS | J Prev Alz Dis 2023;3(10):595-599 | 92 |
EDITORIAL: IMPLICATIONS OF EMERGING USES OF GENETIC TESTING FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;3(10):359-361 | 90 |
VIEWPOINT: DEFINING FDA APPROVED TREATMENTS AS REASONABLE AND NECESSARY: PERSPECTIVES OF INDIVIDUALS LIVING WITH ALZHEIMER’S DISEASE AND CARE PARTNERS | J Prev Alz Dis 2023;3(10):346-348 | 89 |
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2018;5(S1):S1-S196 | 86 |
COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):164-168 | 86 |
NEUROPROTECTIVE EFFECTS OF IVIG AGAINST ALZHEIMER’ S DISEASE VIA REGULATION OF ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULES IN 3XTG-AD MICE | J Prev Alz Dis 2023;3(10):581-594 | 86 |
DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814) | J Prev Alz Dis 2017;4(4):247-254 | 85 |
VALIDATION OF THE COGDRISK INSTRUMENT AS PREDICTIVE OF DEMENTIA IN FOUR GENERAL COMMUNITY-DWELLING POPULATIONS | J Prev Alz Dis 2023;3(10):478-487 | 85 |
COHORT EFFECTS IN ALZHEIMER’S DISEASE TRIALS: AN EMPIRICAL ASSESSMENT UTILIZING DATA FROM THE ALZHEIMER’S DISEASE COOPERATIVE STUDY | J Prev Alz Dis 2023;3(10):471-477 | 83 |
EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(3):151-152 | 82 |
THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTS | J Prev Alz Dis 2019;6(4):223-227 | 81 |
WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE) | J Prev Alz Dis 2018;5(4):214-215 | 80 |
TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY | J Prev Alz Dis 2019;6(3):192-197 | 78 |
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2014;1(3):214-296 | 75 |
EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE? | J Prev Alz Dis 2019;6(3):153-154 | 75 |
Editorial: We Have Turned the Corner | J Prev Alz Dis 2022;9(S1):S5-S6 | 71 |
EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS | J Prev Alz Dis 2019;6(3):155-156 | 70 |
Editorial: Current Themes and Controversies in the Alzheimer’s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022 | J Prev Alz Dis 2022;9(S1):S3-S4 | 68 |
EDITORIAL: DIETARY CHOLESTEROL AND DEMENTIA RISK | J Prev Alz Dis 2023;4(10):746-747 | 68 |
DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB) | J Prev Alz Dis 2018;5(1):15-20 | 67 |
MULTIMODAL PRECISION PREVENTION - A NEW DIRECTION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):718-728 | 66 |
BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2018;5(2):103-109 | 64 |
TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE: SENOLYTICS | J Prev Alz Dis 2023;4(10):633-646 | 64 |
TWO-YEAR PROGNOSTIC UTILITY OF PLASMA P217+TAU ACROSS THE ALZHEIMER’S CONTINUUM | J Prev Alz Dis 2023;4(10):828-836 | 62 |
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(3):184-188 | 58 |
TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS | J Prev Alz Dis 2018;5(1):31-35 | 58 |
LECANEMAB CLARITY AD: QUALITY-OF-LIFE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):771-777 | 57 |
SAFETY, TOLERABILITY, PHARMACOKINETICS AND QUANTITATIVE ELECTROENCEPHALOGRAPHY ASSESSMENT OF ACD856, A NOVEL POSITIVE ALLOSTERIC MODULATOR OF TRK-RECEPTORS FOLLOWING MULTIPLE DOSES IN HEALTHY SUBJECTS | J Prev Alz Dis 2023;4(10):778-789 | 55 |
GEROSCIENCE AND ALZHEIMER’S DISEASE DRUG DEVELOPMENT | J Prev Alz Dis 2023;4(10):620-632 | 55 |
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):180-181 | 54 |
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):8-14 | 52 |
EDITORIAL: THE STATE OF ALZHEIMER’S RESEARCH AND THE PATH FORWARD | J Prev Alz Dis 2023;4(10):617-619 | 52 |
TARGETING ENDOGENOUS MECHANISMS OF BRAIN RESILIENCE FOR THE TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):699-705 | 52 |
FIBRIN-TARGETING IMMUNOTHERAPY FOR DEMENTIA | J Prev Alz Dis 2023;4(10):647-660 | 51 |
ASURE CLINICAL TRIAL PROTOCOL: A RANDOMIZED, PLACEBOCONTROLLED, PROOF-OF-CONCEPT STUDY AIMING TO EVALUATE SAFETY AND TARGET ENGAGEMENT FOLLOWING ADMINISTRATION OF TW001 IN EARLY ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2023;4(10):669-674 | 51 |
THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS | J Prev Alz Dis 2014;1(3):181-202 | 50 |
A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED | J Prev Alz Dis 2017;4(1):51-57 | 49 |
ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018 | J Prev Alz Dis 2019;6(3):198-203 | 49 |
CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISM | J Prev Alz Dis 2017;4(4):211-212 | 48 |
COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSY | J Prev Alz Dis 2019;6(3):182-184 | 48 |
OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCH | J Prev Alz Dis 2018;5(1):2-4 | 47 |
PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS? | J Prev Alz Dis 2018;5(3):158-159 | 47 |
MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATION | J Prev Alz Dis 2019;6(3):185-191 | 47 |
ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEAD | J Prev Alz Dis 2015;2(2):78-79 | 46 |
OPPORTUNITIES FOR CELLULAR REJUVENATION IN ALZHEIMER’S DISEASE: HOW EPIGENETIC REPROGRAMMING AND CHAPERONE-MEDIATED AUTOPHAGY ARE ENABLING NEXT GENERATION THERAPEUTIC APPROACHES | J Prev Alz Dis 2023;4(10):661-668 | 46 |
IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):40-45 | 45 |
ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY | J Prev Alz Dis 2019;6(2):85-89 | 45 |
A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):192-201 | 44 |
E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS | J Prev Alz Dis 2014;1(2):110-116 | 43 |
LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONS | J Prev Alz Dis 2016;3(2):92-100 | 43 |
GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA | J Prev Alz Dis 2016;3(4):185-187 | 43 |
COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ? | J Prev Alz Dis 2019;6(3):174-176 | 43 |
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP | J Prev Alz Dis 2019;6(3):179 | 43 |
RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):103-114 | 41 |
DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRY | J Prev Alz Dis 2015;2(4):216-218 | 41 |
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):168-175 | 40 |
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2015;2(1):2-3 | 39 |
VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY | J Prev Alz Dis 2016;3(2):75-84 | 39 |
RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2017;4(4):213-214 | 39 |
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIAL | J Prev Alz Dis 2018;5(2):134-136 | 39 |
THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY: A DIGITAL INTERVENTION TO INCREASE RESEARCH PARTICIPATION OF BLACK AMERICAN PARTICIPANTS IN THE BRAIN HEALTH REGISTRY | J Prev Alz Dis 2023;4(10):847-856 | 39 |
THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CARE | J Prev Alz Dis 2015;2(3):199-211 | 38 |
PROTOCOL FOR THE BRAIN HEALTH SUPPORT PROGRAM STUDY OF THE CANADIAN THERAPEUTIC PLATFORM TRIAL FOR MULTIDOMAIN INTERVENTIONS TO PREVENT DEMENTIA (CANTHUMBS UP): A PROSPECTIVE 12-MONTH INTERVENTION STUDY | J Prev Alz Dis 2023;4(10):875-885 | 38 |
MODULATION OF MITOCHONDRIAL FUNCTION AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES | J Prev Alz Dis 2023;4(10):675-685 | 38 |
PREVENTION: HOW THE PARADIGM IS SHIFTING | J Prev Alz Dis 2014;1(1):51-55 | 37 |
COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS | J Prev Alz Dis 2019;6(3):177-178 | 37 |
EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):2-3 | 36 |
PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONS | J Prev Alz Dis 2018;5(1):5-7 | 36 |
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):243-259 | 35 |
NEUROINFLAMMATION, ITS ROLE IN ALZHEIMER’S DISEASE AND THERAPEUTIC STRATEGIES | J Prev Alz Dis 2023;4(10):686-698 | 35 |
NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES | J Prev Alz Dis 2015;2(3):155-156 | 34 |
HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATION | J Prev Alz Dis 2016;3(3):123-126 | 34 |
FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS | J Prev Alz Dis 2017;4(2):100-108 | 34 |
GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):67-68 | 34 |
EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL? | J Prev Alz Dis 2014;1(2):62-64 | 33 |
INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):38-45 | 33 |
METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES | J Prev Alz Dis 2015;2(2):91-102 | 33 |
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERS | J Prev Alz Dis 2015;2(1):51-55 | 32 |
TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONS | J Prev Alz Dis 2015;2(3):163-164 | 32 |
AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 | J Prev Alz Dis 2016;3(4):181-184 | 31 |
PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDY | J Prev Alz Dis 2019;6(4):256-266 | 31 |
EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STU | J Prev Alz Dis 2014;1(2):59-61 | 30 |
PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEW | J Prev Alz Dis 2016;3(3):160-163 | 30 |
CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE | | 30 |
EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2018;5(1):26-30 | 30 |
IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARS | J Prev Alz Dis 2019;6(4):221-222 | 30 |
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):228-231 | 30 |
THE CRITICAL ROLE OF BIOMARKERS FOR DRUG DEVELOPMENT TARGETING THE BIOLOGY OF AGING | J Prev Alz Dis 2023;4(10):729-742 | 30 |
EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASE | J Prev Alz Dis 2014;1(1):4-5 | 29 |
PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):56-63 | 28 |
COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS | J Prev Alz Dis 2014;1(2):68 | 28 |
STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGES | J Prev Alz Dis 2015;2(3):157-159 | 28 |
DIETARY FACTORS AND COGNITIVE DECLINE | J Prev Alz Dis 2016;3(1):53-64 | 28 |
THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS | J Prev Alz Dis 2016;3(1):8-12 | 28 |
LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIES | J Prev Alz Dis 2015;2(4):214-215 | 28 |
PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONS | J Prev Alz Dis 2018;5(2):90-94 | 28 |
MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE | J Prev Alz Dis 2018;5(2):110-119 | 28 |
A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):120-133 | 28 |
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):8-10 | 27 |
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):138-140 | 27 |
AMYLOID AND TAU BIOMARKERS IN CSF | J Prev Alz Dis 2015;2(1):46-50 | 27 |
INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(1):4-6 | 27 |
MRI FOR PRE-DEMENTIA TRIALS | J Prev Alz Dis 2016;3(1):5-7 | 27 |
DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):149-154 | 26 |
CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACH | J Prev Alz Dis 2018;5(4):245-252 | 26 |
LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGING | J Prev Alz Dis 2020;7(1):21-28 | 26 |
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED? | J Prev Alz Dis 2014;1(1):6-7 | 25 |
BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIAL | J Prev Alz Dis 2015;2(1):11-16 | 25 |
IMMUNOTHERAPY OF AD: ALUM DEMAIN? | J Prev Alz Dis 2015;2(2):80-81 | 25 |
COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES | J Prev Alz Dis 2017;4(1):3-11 | 25 |
REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH | J Prev Alz Dis 2019;6(1):2-15 | 25 |
FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWS | J Prev Alz Dis 2019;6(2):121-134 | 25 |
NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENT | J Prev Alz Dis 2015;2(3):160-162 | 24 |
TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(3):160-164 | 24 |
IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTS | J Prev Alz Dis 2015;2(4):220-226 | 23 |
WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):20-23 | 23 |
TEA FOR ALZHEIMER PREVENTION | J Prev Alz Dis 2015;2(2):136-141 | 23 |
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES | J Prev Alz Dis 2016;3(1):13-19 | 23 |
BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALS | J Prev Alz Dis 2016;3(2):66-67 | 23 |
THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2018;5(1):49-54 | 23 |
ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.org | J Prev Alz Dis 2014;1(2):91-98 | 22 |
COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELP | J Prev Alz Dis 2014;1(2):69-70 | 22 |
ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | J Prev Alz Dis 2014;1(3):141-142 | 22 |
FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIA | J Prev Alz Dis 2014;1(3):212-213 | 22 |
COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW | J Prev Alz Dis 2015;2(2):142-152 | 22 |
DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITION | J Prev Alz Dis 2017;4(3):138-139 | 22 |
A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASE | J Prev Alz Dis 2014;1(2):99-109 | 21 |
DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING | J Prev Alz Dis 2014;1(2):117-123 | 21 |
ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVE | J Prev Alz Dis 2016;3(4):178-180 | 21 |
ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY | J Prev Alz Dis 2017;4(2):93-99 | 21 |
ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT | J Prev Alz Dis 2018;5(2):137-141 | 21 |
PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTS | J Prev Alz Dis 2020;4(7):256-264 | 21 |
COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY | J Prev Alz Dis 2014;1(2):66-67 | 20 |
A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2014;1(3):143-150 | 20 |
ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2015;2(2):121-127 | 20 |
THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(4):242-253 | 20 |
GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIA | J Prev Alz Dis 2017;4(1):16-20 | 20 |
ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY | J Prev Alz Dis 2014;1(2):74-79 | 19 |
COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPAN | J Prev Alz Dis 2015;2(1):71-76 | 19 |
COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDY | J Prev Alz Dis 2018;5(1):55-64 | 19 |
PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY | J Prev Alz Dis 2019;6(1):34-41 | 19 |
THINKING ABOUT COGNITIVE FRAILTY | J Prev Alz Dis 2015;2(1):7-10 | 18 |
A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALS | J Prev Alz Dis 2016;3(2):101-104 | 18 |
PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDY | J Prev Alz Dis 2018;5(4):236-244 | 18 |
DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS? | J Prev Alz Dis 2019;6(1):20-26 | 18 |
AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT | J Prev Alz Dis 2019;6(1):63-69 | 18 |
COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATE | J Prev Alz Dis 2014;1(1):11-12 | 17 |
AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIA | J Prev Alz Dis 2015;2(3):172-177 | 17 |
NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDY | J Prev Alz Dis 2016;3(3):151-159 | 17 |
THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):189-191 | 17 |
SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERS | J Prev Alz Dis 2017;4(3):134-135 | 17 |
BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA? | J Prev Alz Dis 2014;1(3):151-159 | 16 |
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON | J Prev Alz Dis 2014;1(3):176-180 | 16 |
INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDY | J Prev Alz Dis 2016;3(3):127-132 | 16 |
FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTION | J Prev Alz Dis 2018;5(4):225-230 | 16 |
REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERS | J Prev Alz Dis 2019;6(2):144-147 | 16 |
DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2019;6(3):204-211 | 16 |
COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDY | J Prev Alz Dis 2019;6(4):237-241 | 16 |
COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ | J Prev Alz Dis 2014;1(2):71-73 | 15 |
CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESE | J Prev Alz Dis 2014;1(3):160-167 | 15 |
CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION | J Prev Alz Dis 2017;4(3):136-137 | 15 |
AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS | J Prev Alz Dis 2018;5(3):197-201 | 15 |
DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED! | J Prev Alz Dis 2018;5(2):95-97 | 15 |
FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIA | J Prev Alz Dis 2020;7(2):104-111 | 15 |
MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):23-32 | 14 |
HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):124-128 | 14 |
JPAD IS MOVING FAST | J Prev Alz Dis 2016;3(1):3-4 | 14 |
ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE? | J Prev Alz Dis 2017;4(1):58-64 | 14 |
EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHT | J Prev Alz Dis 2017;4(4):218-225 | 14 |
WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE? | J Prev Alz Dis 2018;5(3):165-167 | 14 |
INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIA | J Prev Alz Dis 2019;6(1):56-62 | 14 |
IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):135-138 | 14 |
OVERTREATING ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):234-236 | 14 |
PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2022;3(9):400-409 | 14 |
HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDY | J Prev Alz Dis 2015;2(1):24-32 | 13 |
DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDY | J Prev Alz Dis 2017;4(3):143-148 | 13 |
CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECT | J Prev Alz Dis 2018;5(1):36-41 | 13 |
COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONS | J Prev Alz Dis 2018;5(1):42-48 | 13 |
ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3 | J Prev Alz Dis 2018;5(3):184-187 | 13 |
EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):251-255 | 13 |
COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONS | J Prev Alz Dis 2021;2(8):210-217 | 13 |
MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICT | J Prev Alz Dis 2015;2(1):17-23 | 12 |
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT | J Prev Alz Dis 2015;2(1):64-70 | 12 |
THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECT | J Prev Alz Dis 2016;3(2):85-91 | 12 |
SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITION | J Prev Alz Dis 2017;4(2):87-92 | 12 |
COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2018;5(1):71-77 | 12 |
PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIR | J Prev Alz Dis 2017;4(4):215-217 | 12 |
ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2018;5(4):216-224 | 12 |
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED | J Prev Alz Dis 2019;6(2):112-120 | 12 |
GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):2-3 | 12 |
DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3 | J Prev Alz Dis 2020;7(2):122-127 | 12 |
A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSIS | J Prev Alz Dis 2020;7(2):87-94 | 12 |
CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2021;3(8):267-276 | 12 |
THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’S | J Prev Alz Dis 2022;1(9):92-95 | 12 |
THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORS | J Prev Alz Dis 2014;1(1):33-39 | 11 |
THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDY | J Prev Alz Dis 2015;2(3):178-183 | 11 |
NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ? | J Prev Alz Dis 2015;2(3):212 | 11 |
ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST | J Prev Alz Dis 2017;4(1):29-36 | 11 |
ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDY | J Prev Alz Dis 2018;5(1):21-25 | 11 |
EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL | J Prev Alz Dis 2018;5(3):175-183 | 11 |
MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKE | J Prev Alz Dis 2019;6(4):267-273 | 11 |
FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS | J Prev Alz Dis 2020;3(7):195-196 | 11 |
STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2017;4(1):21-28 | 10 |
COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P) | J Prev Alz Dis 2017;4(1):44-50 | 10 |
SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDY | J Prev Alz Dis 2017;4(3):165-173 | 10 |
DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSION | J Prev Alz Dis 2018;5(1):85-86 | 10 |
LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 10 |
DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTING | J Prev Alz Dis 2018;5(3):188-196 | 10 |
BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDY | J Prev Alz Dis 2019;6(1):70-75 | 10 |
IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVES | J Prev Alz Dis 2021;4(8):534-551 | 10 |
INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENE | J Prev Alz Dis 2014;1(1):46-50 | 9 |
CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):80-83 | 9 |
MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTS | J Prev Alz Dis 2016;3(2):105-113 | 9 |
EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY | J Prev Alz Dis 2016;3(4):188 | 9 |
MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWAN | J Prev Alz Dis 2017;4(1):37-43 | 9 |
OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDY | J Prev Alz Dis 2017;4(3):194-200 | 9 |
EXPANDING THE TOOLKIT FOR STUDIES OF AGING | J Prev Alz Dis 2017;4(2):69-70 | 9 |
FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITION | J Prev Alz Dis 2019;6(4):274-282 | 9 |
LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTION | J Prev Alz Dis 2020;7(2):68-69 | 9 |
ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIES | J Prev Alz Dis 2021;3(8):329-334 | 9 |
EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASE | J Prev Alz Dis 2015;2(1):33-37 | 8 |
GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODEL | J Prev Alz Dis 2016;3(1):24-29 | 8 |
ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLY | J Prev Alz Dis 2017;4(2):81-86 | 8 |
POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALS | J Prev Alz Dis 2017;4(3):140-142 | 8 |
STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2) | J Prev Alz Dis 2018;5(2):142-148 | 8 |
RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 8 |
CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2019;6(2):139-143 | 8 |
SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017 | J Prev Alz Dis 2019;6(2):108-111 | 8 |
NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENT | J Prev Alz Dis 2019;6(4):242-247 | 8 |
SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIAL | J Prev Alz Dis 2022;2(9):255-261 | 8 |
EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;4(9):601-616 | 8 |
FORECASTING THE PREVALENCE OF ALZHEIMER’S DISEASE AT MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA STAGES IN FRANCE IN 2022 | J Prev Alz Dis 2023;2(10):259-266 | 8 |
COMMENTARY: FUTURE OF ALZHEIMER’S DISEASE TREATMENT: COMBINATION THERAPY AND PRECISION MEDICINE | J Prev Alz Dis 2023;4(10):743-745 | 8 |
NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS | J Prev Alz Dis 2014;1(2):84-90 | 7 |
LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORS | J Prev Alz Dis 2018;5(4):259-260 | 7 |
GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012 | J Prev Alz Dis 2018;5(4):231-235 | 7 |
MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDY | J Prev Alz Dis 2019;6(2):100-107 | 7 |
SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):283-287 | 7 |
THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUX | J Prev Alz Dis 2020;3(7):199-200 | 7 |
NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATION | J Prev Alz Dis 2021;1(8):110-116 | 7 |
PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;1(8):41-47 | 7 |
SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;2(8):188-193 | 7 |
A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2021;2(8):142-150 | 7 |
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIAL | J Prev Alz Dis 2021;3(8):249-256 | 7 |
PREVENTION OF ALZHEIMER’S DISEASE AND COGNITIVE DECLINE WITH DIET & LIFESTYLE: PROCEEDINGS OF THE A. G. LEVENTIS FOUNDATION CONFERENCE | J Prev Alz Dis 2023;1(10):137-143 | 7 |
ASSOCIATIONS OF STAGES OF OBJECTIVE MEMORY IMPAIRMENT WITH CEREBROSPINAL FLUID AND NEUROIMAGING BIOMARKERS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):112-119 | 7 |
PREDICTIVE UTILITY OF PLASMA AMYLOID AND TAU FOR COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTS | J Prev Alz Dis 2023;2(10):178-185 | 7 |
AGING, SENESCENCE, AND DEMENTIA | J Prev Alz Dis 2022;3(9):523-531 | 6 |
THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER HOSPITAL ALZHEIMER’S PREVENTION REGISTRY | J Prev Alz Dis 2023;2(10):152-161 | 6 |
EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDY | J Prev Alz Dis 2016;3(3):145-150 | 5 |
DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUM | J Prev Alz Dis 2020;3(7):179-183 | 5 |
AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):142-143 | 5 |
A IS FOR AMYLOID | J Prev Alz Dis 2020;3(7):140-141 | 5 |
A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;4(8):495-502 | 5 |
COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIES | J Prev Alz Dis 2021;4(8):503-512 | 5 |
DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019 | J Prev Alz Dis 2022;2(9):306-314 | 5 |
CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2022;3(9):532-541 | 5 |
DEMOGRAPHIC ANALYSIS OF INDUSTRY-SPONSORED ALZHEIMER’S DISEASE TRIAL POPULATIONS IN THE UNITED STATES | J Prev Alz Dis 2023;1(10):130-132 | 5 |
PHARMACOLOGICAL INVENTIONS FOR ALZHEIMER TREATMENT IN THE UNITED STATES OF AMERICA: A REVISION PATENT FROM 2010 – 2020 | J Prev Alz Dis 2023;1(10):50-68 | 5 |
MEDICAL JOURNEY OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DISEASE DEMENTIA: A CROSS-SECTIONAL SURVEY OF PATIENTS, CARE PARTNERS, AND NEUROLOGISTS | J Prev Alz Dis 2023;2(10):162-170 | 5 |
LONGITUDINAL EXPOSURE–RESPONSE MODELING OF MULTIPLE INDICATORS OF ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2023;2(10):212-222 | 5 |
NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUM | J Prev Alz Dis 2023;3(10):401-417 | 5 |
INITIAL EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS RECEIVING ADUCANUMAB FOLLOWING ACCELERATED APPROVAL | J Prev Alz Dis 2023;4(10):765-770 | 5 |
EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):112-121 | 4 |
SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS | J Prev Alz Dis 2020;7(1):4-6 | 4 |
IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT? | J Prev Alz Dis 2021;1(8):52-58 | 4 |
A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2021;2(8):135-141 | 4 |
ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENT | J Prev Alz Dis 2021;3(8):263-266 | 4 |
QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCH | J Prev Alz Dis 2021;3(8):299-305 | 4 |
PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORS | J Prev Alz Dis 2021;4(8):477-482 | 4 |
THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;4(8):436-441 | 4 |
RECRUITMENT OF OLDER AFRICAN AMERICANS IN ALZHEIMER’S DISEASE CLINICAL TRIALS USING A COMMUNITY EDUCATION APPROACH | J Prev Alz Dis 2022;4(9):672-678 | 4 |
US ADULTS’ LIKELIHOOD TO PARTICIPATE IN DEMENTIA PREVENTION DRUG TRIALS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING | J Prev Alz Dis 2023;1(10):34-40 | 4 |
FRUCTOSE CONSUMPTION IS ASSOCIATED WITH A HIGHER RISK OF DEMENTIA AND ALZHEIMER’S DISEASE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2023;2(10):186-192 | 4 |
ADDING THE TOPOGRAPHICAL INFORMATION FROM TAU-PET TO THE A/T/(N) FRAMEWORK: STEPS TOWARDS STAGING AD IN VIVO | J Prev Alz Dis 2023;3(10):381-386 | 4 |
REPRODUCTIVE MARKERS IN ALZHEIMER’S DISEASE PROGRESSION: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2023;3(10):530-535 | 4 |
ASSOCIATION BETWEEN LONGITUDINAL CEREBROSPINAL FLUID ALZHEIMER’S BIOMARKERS AND THE LIFESTYLE FOR BRAIN HEALTH (LIBRA) INDEX: FINDINGS FROM THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA COHORT STUDY (EPAD LCS) | J Prev Alz Dis 2023;3(10):543-550 | 4 |
NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSURE | J Prev Alz Dis 2018;5(1):65-70 | 3 |
EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):95-103 | 3 |
THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):43-46 | 3 |
EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDY | J Prev Alz Dis 2020;7(2):75-81 | 3 |
COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIAL | J Prev Alz Dis 2022;1(9):144-150 | 3 |
REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;1(9):113-118 | 3 |
KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):54-66 | 3 |
INTERVENTION FOR COGNITIVE RESERVE ENHANCEMENT IN DELAYING THE ONSET OF ALZHEIMER’S SYMPTOMATIC EXPRESSION (INCREASE) STUDY: RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF MEDICATION THERAPY MANAGEMENT TARGETING A DELAY IN PRODROMAL DEMENTIA SYMPTOM PROGRESSION | J Prev Alz Dis 2022;4(9):646-654 | 3 |
A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):589-600 | 3 |
LETTER TO THE EDITOR: GENETICALLY DETERMINED ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED RISK OF VARICOSE VEIN: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2022;4(9):816-817 | 3 |
SCREENING OVER SPEECH IN UNSELECTED POPULATIONS FOR CLINICAL TRIALS IN AD (PROSPECT-AD): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2023;2(10):314-321 | 3 |
WHITE MATTER HYPERINTENSITY AS A VASCULAR CONTRIBUTION TO THE AT(N) FRAMEWORK | J Prev Alz Dis 2023;3(10):387-400 | 3 |
EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | | 2 |
EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW | | 2 |
INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROME | J Prev Alz Dis 2021;1(8):48-51 | 2 |
MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALES | J Prev Alz Dis 2021;2(8):169-174 | 2 |
A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):84-91 | 2 |
EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORS | J Prev Alz Dis 2021;2(8):161-168 | 2 |
DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEY | J Prev Alz Dis 2021;2(8):194-198 | 2 |
DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTER | J Prev Alz Dis 2021;3(8):351-361 | 2 |
MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGING | J Prev Alz Dis 2021;3(8):292-298 | 2 |
SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):22-29 | 2 |
IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE? | J Prev Alz Dis 2022;1(9):184 | 2 |
ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2022;2(9):286-296 | 2 |
EVERYDAY FUNCTIONING AND ENTORHINAL AND INFERIOR TEMPORAL TAU BURDEN IN COGNITIVELY NORMAL OLDER ADULTS | J Prev Alz Dis 2022;4(9):801-808 | 2 |
ASSOCIATION OF A MIND DIET WITH BRAIN STRUCTURE AND DEMENTIA IN A FRENCH POPULATION | J Prev Alz Dis 2022;4(9):655-664 | 2 |
ALZHEIMER’S DISEASE CLINICAL TRIAL RESEARCH ADAPTATION FOLLOWING COVID-19 PANDEMIC ONSET: NATIONAL SAMPLE OF ALZHEIMER’S CLINICAL TRIAL CONSORTIUM SITES | J Prev Alz Dis 2022;4(9):665-671 | 2 |
AGE, SEX, HYPERTENSIONANDHDL-CALTERSERUMBACE1ACTIVITY IN COGNITIVELY NORMAL SUBJECTS: IMPLICATIONS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):708-714 | 2 |
PROGRAMMED DEATH OF MICROGLIA IN ALZHEIMER’S DISEASE: AUTOPHAGY, FERROPTOSIS, AND PYROPTOSIS | J Prev Alz Dis 2023;1(10):95-103 | 2 |
RISK ESTIMATES OF DEMENTIA AND ALZHEIMER’S DISEASE AMONG DIFFERENT WHOLE GRAIN FOOD CONSUMPTION CATEGORIES: A PILOT STUDY | J Prev Alz Dis 2023;1(10):133-136 | 2 |
MEDICAL AND PSYCHIATRIC RISK FACTORS FOR DEMENTIA IN VETERANS WITH AND WITHOUT TRAUMATIC BRAIN INJURY (TBI): A NATIONWIDE COHORT STUDY | J Prev Alz Dis 2023;2(10):244-250 | 2 |
A GENETIC VALIDATION OF THE NEURODEGENERATION BIOMARKERS TAU-A AND TAU-C - A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2023;3(10):536-542 | 2 |
HIGH INTAKE OF DIETARY CHOLESTEROL DECREASES THE RISK OF ALL-CAUSE DEMENTIA AND AD DEMENTIA: A RESULTS FROM FRAMINGHAM OFFSPRING COHORT | J Prev Alz Dis 2023;4(10):748-755 | 2 |
PLASMA OLIGOMER Β-AMYLOID AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS ACCORDING TO CEREBRAL AMYLOID DEPOSITION | J Prev Alz Dis 2023;4(10):837-846 | 2 |
GENOTYPIC EFFECTS OF THE TOMM40’523 VARIANT AND APOE ON LONGITUDINAL COGNITIVE CHANGE OVER 4 YEARS: THE TOMMORROW STUDY | J Prev Alz Dis 2023;4(10):886-894 | 2 |
METFORMIN IN THE PREVENTION OF ALZHEIMER’S DISEASE AND ALZHEIMER’S DISEASE RELATED DEMENTIAS | J Prev Alz Dis 2023;4(10):706-717 | 2 |
ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTS | J Prev Alz Dis 2020;7(1):37-42 | 1 |
ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2020;7(1):14-20 | 1 |
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAO | J Prev Alz Dis 2020;7(2):83-86 | 1 |
THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEW | J Prev Alz Dis 2021;1(8):100-109 | 1 |
PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTS | J Prev Alz Dis 2021;1(8):92-99 | 1 |
COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMES | J Prev Alz Dis 2021;1(8):33-40 | 1 |
MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSION | J Prev Alz Dis 2021;2(8):224-233 | 1 |
CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):175-180 | 1 |
CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;3(8):345-350 | 1 |
DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLE | J Prev Alz Dis 2021;3(8):322-328 | 1 |
DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA | J Prev Alz Dis 2021;3(8):335-344 | 1 |
ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIES | J Prev Alz Dis 2021;3(8):277-285 | 1 |
A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANS | J Prev Alz Dis 2021;4(8):457-461 | 1 |
EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDY | J Prev Alz Dis 2021;4(8):442-447 | 1 |
DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICS | J Prev Alz Dis 2022;1(9):119-125 | 1 |
EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIA | J Prev Alz Dis 2022;2(9):338-347 | 1 |
THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2022;1(9):40-48 | 1 |
AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCH | J Prev Alz Dis 2022;1(9):67-76 | 1 |
STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTION | J Prev Alz Dis 2022;2(9):376-384 | 1 |
CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2022;3(9):480-490 | 1 |
INCREASED INCIDENT ALZHEIMER’S DISEASE AMONG INDIVIDUALS WITH VARICOSE VEINS: A POPULATION-BASED COHORT STUDY | J Prev Alz Dis 2022;3(9):441-448 | 1 |
SUBJECTIVE COGNITIVE DECLINE IN A REGISTRY SAMPLE: RELATION TO PSYCHIATRIC HISTORY, LONELINESS, AND PERSONALITY | J Prev Alz Dis 2022;3(9):435-440 | 1 |
EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):410-424 | 1 |
LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIA | J Prev Alz Dis 2022;3(9):561 | 1 |
ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHING | J Prev Alz Dis 2022;2(9):277-285 | 1 |
SALIVARY ALPHA-AMYLASE ACTIVITY AND MILD COGNITIVE IMPAIRMENT AMONG JAPANESE OLDER ADULTS: THE TOON HEALTH STUDY | J Prev Alz Dis 2022;4(9):752-757 | 1 |
VALIDATION OF THE SAINT LOUIS UNIVERSITY QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS WITH ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):809-812 | 1 |
OBESITY AND BRAIN HEALTH: THE IMPACT OF METABOLIC SYNDROME AND CARDIORESPIRATORY FITNESS ON COGNITIVE PERFORMANCES IN MIDDLE-AGED OBESE WOMEN | J Prev Alz Dis 2022;4(9):701-707 | 1 |
ASSOCIATION OF PREECLAMPSIA WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE AMONG WOMEN IN THE FRAMINGHAM OFFSPRING STUDY | J Prev Alz Dis 2022;4(9):725-730 | 1 |
OBJECTIVE AND SUBJECTIVE MEASUREMENTS OF MOTOR FUNCTION: RESULTS FROM THE HELIAD STUDY | J Prev Alz Dis 2022;4(9):743-751 | 1 |
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ICAPAMESPIB, A SELECTIVE EPICHAPEROME INHIBITOR, IN HEALTHY ADULTS | J Prev Alz Dis 2022;4(9):635-645 | 1 |
DELAYED DECLINE OF COGNITIVE FUNCTION BY ANTIHYPERTENSIVE AGENTS: A COHORT STUDY LINKED WITH GENOTYPE DATA | J Prev Alz Dis 2022;4(9):679-691 | 1 |
SOCIOECONOMIC STATUS AND RISKS OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 39 PROSPECTIVE STUDIES | J Prev Alz Dis 2023;1(10):83-94 | 1 |
EMBRYO SELECTION FOR A CARRIER OF AN EARLY-ONSET ALZHEIMER’S DISEASE-ASSOCIATED MUTATION IN THE PSEN1 GENE | J Prev Alz Dis 2023;1(10):144-147 | 1 |
ERRATUM TO: CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2023;1(10):150 | 1 |
ERRATUM TO: ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):151 | 1 |
SUBJECTIVE COGNITIVE COMPLAINTS: COMPARING THE RELATION BETWEEN SELF-REPORTED VERSUS INFORMANTREPORTED SUBJECTIVE COGNITIVE COMPLAINTS AND COGNITIVE PERFORMANCES IN COGNITIVELY UNIMPAIRED, MILD COGNITIVE IMPAIRMENT AND POPULATIONS WITH DEMENTIA | J Prev Alz Dis 2023;3(10):562-570 | 1 |
EXPECTANCY DOES NOT PREDICT 18-MONTH TREATMENT OUTCOMES WITH COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT | | 1 |
ASSOCIATION OF LONELINESS WITH COGNITIVE FUNCTIONS | J Prev Alz Dis 2023;4(10):903-908 | 1 |
ADULT RENAL DYSFUNCTION AND RISK OF DEMENTIA OR COGNITIVE DECLINE: BRAIN-KIDNEY AXIS HYPOTHESIS BASED ON A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;3(10):443-452 | 1 |
USEFULNESS OF COMMUNITY PHARMACY FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT IN OLDER PEOPLE USING THE IQCODE QUESTIONNAIRE | J Prev Alz Dis 2023;3(10):488-496 | 1 |
TEN YEARS AFTER THE NATIONAL ALZHEIMER’S PLAN: DEMENTIA REMAINS A HIDDEN SYNDROME IN FRANCE | J Prev Alz Dis 2023;3(10):600-606 | 1 |
HIGH-FAT DIET-INDUCED DIABETIC CONDITIONS EXACERBATE COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF ALZHEIMER’S DISEASE VIA A SPECIFIC TAU PHOSPHORYLATION PATTERN | | 1 |
A RANDOMIZED PROSPECTIVE SURVEY TARGETING KNOWLEDGE, BARRIERS, FACILITATORS AND READINESS TO PARTICIPATION IN DEMENTIA RESEARCH | J Prev Alz Dis 2023;4(10):790-799 | 1 |
SOCIAL DETERMINANTS OF HEALTH AMONG OLDER ADULTS WITH DEMENTIA IN URBAN AND RURAL AREAS | J Prev Alz Dis 2023;4(10):895-902 | 1 |